NCT00787761 · REGISTRY CONDITION SEARCH

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2012-10-01

RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before the transplant and tacrolimus and methotrexate after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with cyclophosphamide, busulfan, and fludarabine works in treating patients with hematological cancer or kidney cancer undergoing donor stem cell transplant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation

→

outcome · POSTED

T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)

→

outcome · POSTED

T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)

→

outcome · POSTED

Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease

→

outcome · POSTED

Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)

→

outcome · POSTED

Non-relapse Mortality (NRM) at Day 180 Post-transplantation

→

outcome · POSTED

Disease-free Survival (DFS) at 24 Months

→

outcome · POSTED

Overall Survival (OS) at 24 Months

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of one of the following: * Chronic myeloid leukemia (CML) * Philadelphia chromosome (Ph)- and/or BCR-ABL-positive disease * In chronic or accelerated phase * Suboptimal response to imatinib mesylate (i.e., no hematologic complete response by 3 months, no major cytogenetic response by 6 months, or no complete cytogenetic response by 1 year) * CML in blastic transformation allowed provided patient achieved complete remission (CR) or second chronic phase after treatment with imatinib mesylate or chemotherapy * Chronic lymphocytic leukemia meeting one of the following criteria: * Rai stage III or IV disease * Rai stage I or II disease that failed standard therapy (i.e., disease is progressing after ≥ 1 course of standard therapy) * Non-Hodgkin lymphoma (NHL) meeting one of the following criteria: * Indolent NHL * Clinical stage III or IV disease or bulky stage II disease (i.e., ≥ one lymphoid mass \> 5 cm in ≥ one dimension) * Relapsed after primary therapy OR is refractory to therapy * Aggressive NHL * Is not considered curable with standard chemotherapy or autologous stem cell transplantation (i.e., relapsed after autologous stem cell transplantation) * Chemotherapy-responsive disease * Multiple myeloma * Durie-Salmon stage II or III disease * Durie Salmon stage I disease allowed provided β2 microglobulin level \> 3 mg/dL * Acute myeloid leukemia or acute lymphocytic leukemia * In CR (defined as \< 5% blasts in bone marrow and no circulating blasts) AND has any of the following poor prognostic features: * WBC \> 100,000/mm\^3 at presentation * In second or greater remission * Adverse-risk cytogenetics (i.e., Ph1-positive, 11q23 translocation, -5, -7, complex translocations, or other recognized adverse-risk cytogenetics) * Renal cell carcinoma * Stage IV disease * Clear cell morphology * Myelodysplastic syndromes * Bone marrow blasts ≤ 10% on last bone marrow biopsy prior to transplantation * Myeloproliferative disease * Anticipated life expectancy on conventional therapy \< 10 years * No uncomplicated essential thrombocythemia or primary polycythemia * Hodgkin lymphoma * Relapsed after ≥ 1 standard-dose chemotherapy regimen * Not considered curable by autologous stem cell transplantation * No clinical evidence of active CNS involvement * Previously treated leptomeningeal disease allowed provided CSF cytology is negative at the time of assessment for transplantation * Available 6/6 allele match (i.e., HLA-A, B, DRβ1)matched related donor PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% * Bilirubin \< 3 times normal (unless abnormality due to malignancy) * AST and ALT \< 3 times normal (unless abnormality due to malignancy) * Creatinine ≤ 2.0 mg/dL * LVEF ≥ 40% by MUGA or ECHO * DLCO ≥ 40% of predicted * FEV-1 ≥ 50% of predicted * Not pregnant or nursing * Fertile patients must use effective contraception * Deemed to be an appropriate candidate for allogeneic SCT * No evidence of myocardial infarction within the past 6 months * No psychological or social condition that may interfere with study participation * No serious uncontrolled localized or active systemic infection * No second malignancy within the past 3 years except for completely excised nonmelanotic skin cancer or in situ carcinoma of the cervix * No chronic inflammatory disorder requiring the continued use of glucocorticoids or other immunosuppressive medications * No known HIV positivity * No hypersensitivity to E. coli-derived proteins
healthy Volunteers: false
maximum Age: 75 Years
sex: ALL
std Ages: CHILD
ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
intervention Names
Biological: anti-thymocyte globulin
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: nonmyeloablative allogeneic HSCT
label
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
type
EXPERIMENTAL

interventions

arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains \> 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze. Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately. Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration.
name
anti-thymocyte globulin
other Names
Thymoglobulin
ATG
type
BIOLOGICAL
arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
Commercially available in 60 mg/10 mL ampuls. Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL. Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame. IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses.
name
busulfan
type
DRUG
arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection. The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water. Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition. Each dose will be infused over 1-2 hr (depending on the total volume).
name
cyclophosphamide
type
DRUG
arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH. Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration. Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP. Fludarabine will be administered as an IV infusion over 30 minutes.
name
fludarabine phosphate
other Names
Fludara
type
DRUG
arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution. Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL. Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated. Administer via slow IV push.
name
methotrexate
other Names
Amethopterin, MTX
type
DRUG
arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg). Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day. Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F).
name
tacrolimus
other Names
Prograf, FK506
type
DRUG
arm Group Labels
ATG, Cytoxan, Bu/Flu based Allogeneic Transplant
description
As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
name
nonmyeloablative allogeneic HSCT
type
PROCEDURE

Study design

allocation

NON_RANDOMIZED

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 24
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.
measure
Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation
time Frame
Day 30

secondary Outcomes

description
Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.
measure
T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)
time Frame
Day 90
description
Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.
measure
T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)
time Frame
180 days
description
number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence including but not limited to skin rash, elevated liver function tests, nausea/vomiting/diarrhea.
measure
Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease
time Frame
Day 100
description
Patients who had post-transplant complication (GVHD) as seen by clinical evidence including but not limited to skin rash, elevated liver function tests, nausea/vomiting/diarrhea.
measure
Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)
time Frame
2 years
description
non-relapse mortality refers to the death of a patient for causes other than relapsed disease.
measure
Non-relapse Mortality (NRM) at Day 180 Post-transplantation
time Frame
Day 180
description
Disease Free survival is measured by the amount of time a patient spends in a disease free state after being transplanted.
measure
Disease-free Survival (DFS) at 24 Months
time Frame
24 months
description
Overall survival refers to the length of time a patient is alive after transplant regardless of whether they have progressive or relapsed disease.
measure
Overall Survival (OS) at 24 Months
time Frame
24 months

Full study description

brief Summary: RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before the transplant and tacrolimus and methotrexate after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with cyclophosphamide, busulfan, and fludarabine works in treating patients with hematological cancer or kidney cancer undergoing donor stem cell transplant.
detailed Description: OBJECTIVES: * To assess the percentage of patients with hematological malignancies or renal cell carcinoma who achieve \> 90% donor T-cell chimerism at 30 days after treatment with reduced-intensity conditioning comprising low-dose anti-thymocyte globulin, low-dose cyclophosphamide, busulfan, and fludarabine phosphate followed by allogeneic peripheral blood progenitor cell transplantation from a matched related donor. * To assess the incidence of severe (grade 3 or 4) acute graft-versus-host disease (GVHD) and extensive chronic GVHD in these patients. * To assess whether this regimen is associated with reduced transplant-related toxicity and increased tolerability in these patients. * To assess the overall safety of this conditioning regimen as measured by 6-month transplant-related mortality in these patients. * To determine the efficacy of this regimen in inducing durable remissions in these patients. OUTLINE: * Reduced-intensity conditioning (RIC): Patients receive anti-thymocyte globulin IV over 4-6 hours on day -16 and over 6-8 hours on day -15, fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 3 hours on days -4 and -3, and cyclophosphamide IV over 1-2 hours on day -2. * Transplantation: Patients undergo allogeneic peripheral blood progenitor cell transplantation on day 0. * Graft-vs-host disease (GVHD) prophylaxis: Patients receive oral tacrolimus every 12 hours on days -1 to 90, followed by a taper until day 150. Patients also receive methotrexate IV on days 1, 3, and 6. Blood samples are collected periodically for pharmacokinetic studies of anti-thymocyte globulin and PCR analysis for chimerism. After completion of study therapy, patients are followed periodically for up to 3 years.

Source references

references

citation
Rao SS, Peters SO, Crittenden RB, Stewart FM, Ramshaw HS, Quesenberry PJ. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997 Feb;25(2):114-21.
pmid
9015211
type
BACKGROUND
citation
Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Leisenring W, Shulman H. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997 Apr 15;89(8):3048-54.
pmid
9108426
type
BACKGROUND
citation
Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15;89(12):4531-6.
pmid
9192777
type
BACKGROUND
citation
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63.
pmid
9446633
type
BACKGROUND
citation
McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001 Jun 1;97(11):3390-400. doi: 10.1182/blood.v97.11.3390.
pmid
11369628
type
BACKGROUND
citation
Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park). 2003 Jan;17(1):94-100; discussion 103-7.
pmid
12599934
type
BACKGROUND
citation
Platzbecker U, Ehninger G, Schmitz N, Bornhauser M. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases. Ann Hematol. 2003 Aug;82(8):463-468. doi: 10.1007/s00277-003-0680-7. Epub 2003 Jun 21.
pmid
12910373
type
BACKGROUND
citation
Storb R. Non-myeloablative allogeneic transplantation -- state-of-the-art. Pediatr Transplant. 2004 Jun;8 Suppl 5:12-8. doi: 10.1111/j.1398-2265.2004.00189.x.
pmid
15125701
type
BACKGROUND

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-26150ca5bfe3829f2842
requested nct id
NCT00787761
primary nct id
NCT00787761
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Peripheral+T-Cell+Non-Hodgkin+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
payload sha256
d5f4923e61abf12bf69b2140c19436aab705c0b06f340eaf96dfe6e21dcd522d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-26150ca5bfe3829f2842
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00787761
occurrences
context exact
NCT00787761
end
11
exact text
NCT00787761
start
0
offset unit
unicode_code_points
query cond
Peripheral T-Cell Non-Hodgkin Lymphoma
query disease state id
ds-peripheral-t-cell-non-hodgkin-lymphoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
source file sha256
e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
source json pointer
/studies/77/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0d21732deb00adc2320fde953dd9d8d532be17c612cca0f86dae4e44ea4a043e
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Peripheral+T-Cell+Non-Hodgkin+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-7d3b23fba29fe0f6f2ca
requested nct id
NCT00787761
primary nct id
NCT00787761
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
payload sha256
c9cd981a8dcea9e140b32b7772938b33658af7f690a2e70f2686b3da3bba0281
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-7d3b23fba29fe0f6f2ca
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00787761
occurrences
context exact
NCT00787761
end
11
exact text
NCT00787761
start
0
offset unit
unicode_code_points
query cond
Juvenile Myelomonocytic Leukemia
query disease state id
ds-juvenile-myelomonocytic-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
source json pointer
/studies/85/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0d21732deb00adc2320fde953dd9d8d532be17c612cca0f86dae4e44ea4a043e
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-94b9c969e68471805d0c
requested nct id
NCT00787761
primary nct id
NCT00787761
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
2a95a56a259b4fd2e6a4e9692a97a5b5bdb9affdeab5d0ceaa68e8662d603568
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-94b9c969e68471805d0c
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00787761
occurrences
context exact
NCT00787761
end
11
exact text
NCT00787761
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/611/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0d21732deb00adc2320fde953dd9d8d532be17c612cca0f86dae4e44ea4a043e
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b938349f38e732f3d974
requested nct id
NCT00787761
primary nct id
NCT00787761
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
payload sha256
21b81ad06d07c3ec2d56e1f5e34271fff9c922677aeb6a1de0207055949ad7ee
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b938349f38e732f3d974
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00787761
occurrences
context exact
NCT00787761
end
11
exact text
NCT00787761
start
0
offset unit
unicode_code_points
query cond
Acute Undifferentiated Leukemia
query disease state id
ds-acute-undifferentiated-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
source json pointer
/studies/31/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0d21732deb00adc2320fde953dd9d8d532be17c612cca0f86dae4e44ea4a043e
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice